UMB Bank, National Association (the “Trustee”) serves as the successor Trustee under the Contingent Value Rights Agreement, dated as of November 20, 2019 (the “CVR Agreement”), by and between Bristol-Myers Squibb Company (the “Company”) and Equiniti Trust Company (the “Original Trustee”) relating to the Company’s Contingent Value Rights (the “CVRs”).
On December 18, 2020, the Trustee delivered to the Company and the Original Trustee an Instrument of Removal, Appointment and Acceptance, dated as of December 9, 2020, pursuant to which (a) the Original Trustee was removed as Trustee under the CVR Agreement, (b) the Trustee was appointed as successor Trustee under the CVR Agreement, and (c) the Trustee accepted its appointment as Trustee under the CVR Agreement. By notice dated January 4, 2021, the Company notified Holders of the CVRs of the removal of the Original Trustee and the appointment of the Trustee as successor Trustee.
The Trustee has retained Katten Muchin Rosenman LLP to represent the Trustee in connection with its role as the Trustee and with respect to matters relating to the CVR Agreement. In addition, the Trustee has retained Selendy & Gay PLLC as litigation counsel and Cahill Gordon & Reindel LLP as special counsel.
Holders of CVRs (“CVR Holders”) with questions regarding the CVRs may review the information provided in this website.
CVR Holders may also contact the Trustee in writing as follows:
UMB Bank, National Association
120 South Sixth Street, Suite 1400
Minneapolis, MN 55402
Please note that the Trustee may conclude that a specific response to particular inquiries from individual CVR Holders is not consistent with equal and full dissemination of information to all CVR Holders. CVR Holders should not rely on the Trustee as their sole source of information concerning the CVRs. The Trustee makes no recommendations and gives no investment, financial, legal or other advice with respect to the matters herein or as to the CVRs generally.
SUMMARY OF KEY FEATURES